KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Total Non-Current Liabilities (2016 - 2026)

Gsk has reported Total Non-Current Liabilities over the past 18 years, most recently at -$31.0 billion for Q1 2026.

  • For Q1 2026, Total Non-Current Liabilities rose 6.03% year-over-year to -$31.0 billion; the TTM value through Mar 2026 reached -$31.0 billion, up 6.03%, while the annual FY2025 figure was -$31.6 billion, 199.82% down from the prior year.
  • Total Non-Current Liabilities for Q1 2026 was -$31.0 billion at Gsk, up from -$31.6 billion in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $32.0 billion in Q4 2022 and troughed at -$36.1 billion in Q3 2022.
  • A 5-year average of -$20.3 billion and a median of -$31.6 billion in 2025 define the central range for Total Non-Current Liabilities.
  • Biggest five-year swings in Total Non-Current Liabilities: skyrocketed 65.23% in 2022 and later plummeted 199.82% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $32.0 billion in 2022, then fell by 2.33% to $31.2 billion in 2023, then grew by 1.51% to $31.7 billion in 2024, then tumbled by 199.82% to -$31.6 billion in 2025, then grew by 1.86% to -$31.0 billion in 2026.
  • Business Quant data shows Total Non-Current Liabilities for GSK at -$31.0 billion in Q1 2026, -$31.6 billion in Q4 2025, and -$32.7 billion in Q3 2025.